{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:15:44Z","timestamp":1760915744738,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014974","name":"Institute of Biophysics Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014974","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.phrs.2022.106142","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T02:30:21Z","timestamp":1645669821000},"page":"106142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Establishment of an inducible cell line for Hepatitis B virus genotype C2 and its pharmacological responses to interferons"],"prefix":"10.1016","volume":"178","author":[{"given":"Shaodong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.31440","article-title":"Risk scores for hepatocellular carcinoma in chronic hepatitis b: a promise for precision medicine","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106142_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/nsr\/nwu038","article-title":"The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma","volume":"1","author":"Yang","year":"2014","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.phrs.2022.106142_bib3","unstructured":"WHO , Global Hepatitis Report 2017. In, 2017."},{"key":"10.1016\/j.phrs.2022.106142_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-020-0296-6","article-title":"The evolution and clinical impact of hepatitis B virus genome diversity","author":"Revill","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib5","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106142_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull. World Health Organ"},{"issue":"2","key":"10.1016\/j.phrs.2022.106142_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.gastro.2018.07.058","article-title":"Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood","volume":"156","author":"McNaughton","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.phrs.2022.106142_bib8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1099\/jgv.0.001147","article-title":"Genetic diversity of hepatitis B virus in Yunnan, China: identification of novel subgenotype C17, an intergenotypic B\/I recombinant, and B\/C recombinants","volume":"101","author":"Feng","year":"2020","journal-title":"J. Gen. Virol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106142_bib9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/cid\/cit348","article-title":"High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B","volume":"57","author":"Yotsuyanagi","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106142_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/hep.26635","article-title":"Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults","volume":"59","author":"Ito","year":"2014","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.phrs.2022.106142_bib11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106142_bib13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2007.08.010","article-title":"Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F","volume":"133","author":"Livingston","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib14","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.phrs.2022.106142_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1136\/gut.2008.157149","article-title":"Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China","volume":"57","author":"Zhang","year":"2008","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.phrs.2022.106142_bib16","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JCM.01518-10","article-title":"Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients","volume":"48","author":"Li","year":"2010","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.phrs.2022.106142_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1471-2334-11-262","article-title":"Virologic and clinical characteristics of HBV genotypes\/subgenotypes in 487 Chinese pediatric patients with CHB","volume":"11","author":"Zhong","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2022.106142_bib18","article-title":"Identification of a novel long-acting 4\u2019-modified nucleoside reverse transcriptase inhibitor against HBV","author":"Higashi-Kuwata","year":"2020","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106142_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2018.06.093","article-title":"Cell and animal models for studying hepatitis B virus infection and drug development","volume":"156","author":"Hu","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2016.37","article-title":"Experimental models of hepatitis B and C - new insights and progress","volume":"13","author":"Thomas","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2021.07.030","article-title":"Infection courses, virological features and IFN-\u03b1 responses of HBV genotypes in cell culture and animal models","volume":"75","author":"Zhang","year":"2021","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106142_bib22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2022.106142_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1099\/vir.0.19633-0","article-title":"Genotype C of hepatitis B virus can be classified into at least two subgroups","volume":"85","author":"Huy","year":"2004","journal-title":"J. Gen. Virol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106142_bib24","first-page":"866","article-title":"Relationship of HBsAg subtypes with HBeAg\/anti-HBe status and chronic liver disease. Part I: analysis of 1744 HBsAg carriers","volume":"86","author":"Shiina","year":"1991","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106142_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2006.05.019","article-title":"Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus","volume":"45","author":"Sun","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2022.106142_bib26","article-title":"N-terminal PreS1 Sequence Regulates Efficient Infection of Cell Culture-generated Hepatitis B Virus","author":"Murayama","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106142_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/gutjnl-2019-320096","article-title":"Naturally occurring 5' preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C","volume":"70","author":"Li","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2022.106142_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.antiviral.2019.06.002","article-title":"A quantitative method for hepatitis B virus covalently closed circular DNA enables distinguishing direct acting antivirals from cytotoxic agents","volume":"168","author":"Gao","year":"2019","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.phrs.2022.106142_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s13238-018-0511-1","article-title":"Identification of new type I interferon-stimulated genes and investigation of their involvement in IFN-\u03b2 activation","volume":"9","author":"Zhang","year":"2018","journal-title":"Protein Cell"},{"issue":"5","key":"10.1016\/j.phrs.2022.106142_bib30","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2022.106142_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.00183-17","article-title":"Development of a novel site-specific pegylated interferon beta for antiviral therapy of chronic hepatitis B virus","volume":"61","author":"Tsuge","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.phrs.2022.106142_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/infdis\/jiz143","article-title":"Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus-infected hepatocytes","volume":"220","author":"Bockmann","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2022.106142_bib33","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/JVI.01998-10","article-title":"Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells","volume":"85","author":"Mao","year":"2011","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106142_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","article-title":"Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication","volume":"72","author":"Wang","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106142_bib35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.21187","article-title":"Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication","volume":"43","author":"Bonvin","year":"2006","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106142_bib36","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.celrep.2019.04.063","article-title":"Guanylate-binding proteins 2 and 5 exert broad antiviral activity by inhibiting Furin-mediated processing of viral envelope proteins","volume":"27","author":"Braun","year":"2019","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.phrs.2022.106142_bib37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of interferon-\u03b1 subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-\u03b1 and interferon-\u03b3 signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106142_bib38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/j.gastro.2007.12.044","article-title":"Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers","volume":"134","author":"Deng","year":"2008","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.phrs.2022.106142_bib39","doi-asserted-by":"crossref","first-page":"10588","DOI":"10.1128\/JVI.02489-06","article-title":"Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons","volume":"81","author":"Jost","year":"2007","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106142_bib40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/hep.25608","article-title":"MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106142_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006296","article-title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA","volume":"13","author":"Liu","year":"2017","journal-title":"PLoS Pathog."},{"issue":"6176","key":"10.1016\/j.phrs.2022.106142_bib42","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.phrs.2022.106142_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003494","article-title":"Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein","volume":"9","author":"Mao","year":"2013","journal-title":"PLoS Pathog."},{"issue":"17","key":"10.1016\/j.phrs.2022.106142_bib44","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.phrs.2022.106142_bib45","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.30897","article-title":"Nuclear sensor interferon-inducible protein 16 inhibits the function of hepatitis B virus covalently closed circular DNA by integrating innate immune activation and epigenetic suppression","volume":"71","author":"Yang","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2022.106142_bib46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2008.10.048","article-title":"Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes","volume":"136","author":"Sugiyama","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.phrs.2022.106142_bib47","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/gutjnl-2019-318278","article-title":"Quasispecies characteristic in \"a\" determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case-control study","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.phrs.2022.106142_bib48","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/JCM.02157-06","article-title":"Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China","volume":"45","author":"Wang","year":"2007","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.phrs.2022.106142_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1084\/jem.20200840","article-title":"Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers","volume":"217","author":"Hehle","year":"2020","journal-title":"J. Exp. Med"},{"issue":"17","key":"10.1016\/j.phrs.2022.106142_bib50","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.phrs.2022.106142_bib51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jgh.12060","article-title":"Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)","volume":"28","author":"Couzigou","year":"2013","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:30:12Z","timestamp":1760913012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822000871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":51,"alternative-id":["S1043661822000871"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106142","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment of an inducible cell line for Hepatitis B virus genotype C2 and its pharmacological responses to interferons","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106142"}}